

1 **Clinical and Laboratory Profiles of 75 Hospitalized Patients with Novel**
2 **Coronavirus Disease 2019 in Hefei, China**

3 Zonghao Zhao^{1, a}, Jiajia Xie^{2, a}, Ming Yin^{3, 4, a}, Yun Yang^{3, 4}, Hongliang He¹, Tengchuan Jin⁵,
4 Wenting Li¹, Xiaowu Zhu⁶, Jing Xu¹, Changcheng Zhao⁷, Lei Li¹, Yi Li¹, Hylemariam
5 Mihiretie Mengist⁵, Ayesha Zahid⁵, Ziqin Yao¹, Chengchao Ding⁸, Yingjie Qi⁷, Yong Gao⁹ *,
6 Xiaoling Ma⁷ *

7 ¹ Department of Infectious Diseases, The First Affiliated Hospital of USTC, Division of Life
8 Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui,
9 230001, China;

10 ² Department of Dermatology, The First Affiliated Hospital of USTC, Division of Life
11 Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui,
12 230001, China;

13 ³ Department of ICU, The First Affiliated Hospital of USTC, Division of Life Sciences and
14 Medicine, University of Science and Technology of China, Hefei, Anhui, 230000, China;

15 ⁴ Department of ICU, Hefei Infectious Diseases Hospital, Hefei, Anhui, 230000, China;

16 ⁵ Laboratory of Structural Immunology, Division of Life Sciences and Medicine, University
17 of Science and Technology of China (USTC), Hefei, Anhui, 230027, China;

18 ⁶ Department of Infectious Diseases, Hefei Infectious Diseases Hospital, Hefei, Anhui,
19 230000, China;

20 ⁷ Department of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life
21 Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui,
22 230001, China;

23 ⁸ The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University
24 of Science and Technology of China, Hefei, Anhui, 230001, China;

25 ⁹ Department of Infectious Diseases, The First Affiliated Hospital of USTC, Division of Life
26 Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui,

27 230000, China.

28

29 ^aThe first author of this article.

30 * Corresponding Author: Yong Gao, Department of Infectious Diseases, The First Affiliated
31 Hospital of USTC, Division of Life Sciences and Medicine, University of Science and
32 Technology of China, Hefei, Anhui, 230000, China (ygao387@ustc.edu.cn).

33 Xiaoling Ma, Department of Laboratory Medicine, The First Affiliated Hospital of USTC,
34 Division of Life Sciences and Medicine, University of Science and Technology of China,
35 Hefei, Anhui, 230001, China (xiaolingma@126.com).

36 **Abstract**

37 The outbreak of the novel coronavirus disease 2019 (COVID-19) infection began in
38 December 2019 in Wuhan, and rapidly spread to many provinces in China. The
39 number of cases has increased markedly in Anhui, but information on the clinical
40 characteristics of patients is limited. We reported 75 patients with COVID-19 in the
41 First Affiliated Hospital of USTC from Jan 21 to Feb 16, 2020, Hefei, Anhui Province,
42 China. COVID-19 infection was confirmed by real-time RT-PCR of respiratory
43 nasopharyngeal swab samples. Epidemiological, clinical and laboratory data were
44 collected and analyzed. Of the 75 patients with COVID-19, 61 (81.33%) had a direct
45 or indirect exposure history to Wuhan. Common symptoms at onset included fever
46 (66 [88.0%] of 75 patients) and dry cough (62 [82.67%]). Of the patients without
47 fever, cough could be the only or primary symptom. The most prominent laboratory
48 abnormalities were lymphopenia, decreased percentage of lymphocytes (LYM%),
49 decreased CD4⁺ and CD8⁺ T cell counts, elevated C-reactive protein (CRP) and
50 lactate dehydrogenase (LDH). Patients with elevated interleukin 6 (IL-6) showed
51 significant decreases in the LYM%, CD4⁺ and CD8⁺ T cell counts. Besides, the
52 percentage of neutrophils, CRP, LDH and Procalcitonin levels increased significantly.
53 We concluded that COVID-19 could cause different degrees of hematological

54 abnormalities and damage of internal organs. Hematological profiles including LYM,
55 LDH, CRP and IL-6 could be indicators of diseases severity and evaluation of
56 treatment effectiveness. Antiviral treatment requires a comprehensive and supportive
57 approach. Further targeted therapy should be determined based on individual clinical
58 manifestations and laboratory indicators.

59 **Keywords:** coronavirus disease 2019, clinical profile, hematological abnormality,
60 interleukin 6

61 **Introduction**

62 Since Dec 2019, a series of acute respiratory illness outbreaks in Wuhan, Hubei
63 Province, China [1, 2]. The disease has been subsequently identified in other
64 provinces in China, and other counties. On Jan 7, a novel coronavirus was identified
65 by deep sequencing analysis of samples from throat swabs and lower respiratory tract.
66 The disease caused by the novel virus is now named by WHO as novel coronavirus
67 disease 2019 (COVID-19). Epidemiological research shows that all infected patients
68 had travel or residence records in Wuhan, suggesting the possibility of
69 person-to-person transmission [3]. By Feb 22, 2020, more than 75,000 confirmed
70 cases, including 1716 health-care workers, have been identified in China. And 989
71 patients have been diagnosed in Anhui Province, including 6 deaths.

72 The novel coronavirus is an enveloped non-segmented positive sense RNA virus
73 belonging to the betacoronaviruses. The well-known atypical pneumonia virus
74 (SARS-CoV) and Middle East Respiratory Syndrome Virus (MERS-CoV) are also
75 betacoronaviruses [4]. Clinical manifestations of COVID-19 include fever, dry cough,
76 myalgia and fatigue. Symptoms of headache, expectoration, and diarrhea seem to less
77 common. Radiographic evidence suggested pneumonia. About half of patients have
78 developed severe pneumonia. Nearly one third of patients require intensive care
79 because of acute respiratory distress syndrome (ARDS) or multiple organ failure [1,
80 5].

81 At present, there are relatively few reports about novel coronavirus pneumonia in

82 Anhui Province. Here, we described the epidemiological, clinical and laboratory
83 characteristics of 75 COVID-19 confirmed patients admitted to the First Affiliated
84 Hospital of USTC, Hefei. This study will be beneficial for the diagnosis and treatment
85 of COVID-19 patients in clinical practice.

86 **Methods**

87 **Patients**

88 In this study, we eventually enrolled 75 patients from the First Affiliated Hospital
89 of USTC between Jan 21, and Feb 16, 2020. Most patients came to the hospital
90 because of fever or respiratory symptoms. Our clinical team consulted and recorded
91 their epidemiological history in detail regarding to whether they had been to Wuhan
92 or exposed to people who came from Wuhan recently. Nasopharyngeal and throat
93 swabs were taken for respiratory pathogens test. The physical findings, hematological,
94 biochemical and radiological results were also recorded. All patients were identified
95 as laboratory-confirmed COVID-19 infection. All patients enrolled in this study were
96 diagnosed according to World Health Organization interim guidance. The study was
97 approved by the Ethics Committee of the First Affiliated Hospital of USTC .

98 **Procedures**

99 Respiratory nasopharyngeal swabs were collected and the presence of COVID-19
100 was detected by next real-time RT-PCR methods. Viral RNA was extracted using
101 QIAamp RNA virus Kit (Qiagen, Heiden, Germany). The diagnostic test was done
102 using a commercial coronavirus test kit (Shenzhen Huada Yinyuan Pharmaceutical
103 Technology Co., Ltd., Shenzhen). The specific primers and probe targeted to
104 nucleocapsidprotein (N) were used and the sequences were as follows: forward primer
105 5'-GGGGAACTTCTCCTGCTAGAAT-3'; reverse primer
106 5'-CAGACATTTTGCTCTCAAGCTG-3'; and the probe
107 5'-FAM-TTGCTGCTGCTTGACAGATT-TAMRA-3'. Conditions for the
108 amplifications were 50°C for 20 min, 95°C for 10 min, followed by 40 cycles of
109 denaturation at 95°C for 15 s and extending and collecting fluorescence signal at 60°C

110 for 30 s. A cycle threshold value (Ct-value) less than 37 was defined as a positive test
111 result, and a Ct-value of 40 or more was defined as a negative test. A medium load,
112 defined as a Ct-value of 37 to less than 40, requires a retesting according to the
113 guideline of Chinese Centers for Disease Control and Prevention
114 (http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html).

115 We also examined other respiratory viruses, including influenza, avian influenza,
116 respiratory syncytial virus, adenovirus, parainfluenza virus, SARS-CoV and
117 MERS-CoV, with realtime RT-PCR. Hematological parameters including blood
118 routine, blood biochemistry, coagulation profile, and infection-related biomarkers
119 were recorded. Plasma cytokine interleukin 6 (IL-6) levels were detected by ELISA.
120 And the CD4⁺ and CD8⁺ T cell subsets were counted using flow cytometry.

121 **Statistical analysis**

122 We presented continuous measurements as median (IQR) and categorical variables
123 as number (%). Continuous variables were analyzed using the Mann-Whitney test.
124 For laboratory results, we also assessed whether the measurements were outside the
125 normal range. Graphpad prism 8.3 was used for all analyses. A two-sided α of less
126 than 0.05 was considered statistically significant.

127 **Results**

128 Totally, 75 patients diagnosed with COVID-19 were included in this study. Among
129 them, 61 (81.33%) patients had been to Wuhan or exposed to people who came from
130 Wuhan. The median age of the patients was 47 years. Among them, 36 (48%) were
131 aged 40-59 years, 25 (33.3 %) were aged 20-39 years, 11 (14.67%) were aged 60-79
132 years. The youngest patient aged 16 years and the oldest aged 91 years. More than
133 half of the participants were men (42 [56%]). Twenty-nine (38.67%) patients had one
134 or more chronic diseases, including cardiovascular and cerebrovascular disease,
135 diabetes, chronic kidney disease, respiratory system disease, nervous system disease,
136 chronic liver diseases, and malignant tumor (Table 1).

137 Most patients admitted to hospital because of fever (66 [88.0%]) and dry cough (62
138 [82.67%]). Nearly a third of patients had chest tightness (24 [32.0%]). And 20
139 (26.67%) patients had all the three symptoms mentioned above. Less common
140 symptoms included sputum production (22 [29.33%]), fatigue (17 [22.67%]), muscle
141 soreness (9 [12.0%]) and poor appetite (9 [12.0%]). Other symptoms included
142 diarrhea, sore throat, headache, shortness of breath and stomach ache. Nine patients
143 had a body temperature below 37.3°C, and all of them had symptom of dry cough.
144 Only a small proportion had sputum, fatigue, poor appetite and chest tightness (Table
145 2).

146 The blood counts of patients on admission showed leucopenia (white blood cell
147 counts below the normal range; 12 [16.0%]). Twenty-nine (38.67%) patients showed
148 increased neutrophil percentage (NEU%). Over half of the patients (40 [53.33%])
149 showed lymphopenia (lymphocytes counts less than $1.1 \times 10^9/L$). However, no patients
150 had increased lymphocytes counts. Thirty-one (41.33%) and 28 (37.33%) patients
151 showed decreased counts of CD4⁺ and CD8⁺ T cell levels, respectively. The
152 CD4⁺/CD8⁺ ratio was below the normal range in 11 (14.67%) patients. Haemoglobin
153 were decreased in 11 (14.67%) patients and increased in 18 (24%) patients. Platelets
154 were below the normal range in 14 (18.67%) patients and above the normal range in
155 only 2 (2.67%) patients. Most patients showed impaired coagulation function.
156 Activated partial thromboplastin time (APTT) was longer in 44 (58.67%) patients and
157 prothrombin time (PT) was longer in 30 (40%) patients (Table 3).

158 Fifteen patients had differing degrees of liver function abnormality, with alanine
159 aminotransferase (ALT) or aspartate aminotransferase (AST) above the normal range.
160 One patient with no underlying disease had a serious liver function damage (ALT 171
161 U/L, AST 60 U/L). Nearly half of patients showed abnormal myocardial zymogram,
162 with the elevation of lactate dehydrogenase (LDH) in 33 (44%) patients and the
163 elevation of Troponin I in 13 (17.33%) patients. Fifteen (20%) patients had different
164 degrees of renal function damage with elevated serum creatinine. One patient with
165 uremia had creatinine level of 1561 $\mu\text{mol/L}$ (Table 3). These findings suggested that

166 the internal organs could also be potential targets of COVID-19.

167 Regarding the infection index, most patients showed elevated C-reactive protein
168 (CRP) and Erythrocyte sedimentation rate (ESR) levels. Procalcitonin (PCT) was
169 elevated in 2 out of 59 patients. Forty-nine patients were tested for IL-6, and 14
170 (28.57%) of them showed levels above the normal range (Table 3). Further analysis
171 showed that the 14 patients had significant decreases in lymphocytes percentage,
172 CD4⁺ and CD8⁺ T cell counts, compared to those with normal IL-6 range. Besides, the
173 NEU%, CRP and LDH levels increased significantly (Table 4; Figure 1). PCT values
174 were within normal range in both two groups. These data indicated that there might be
175 correlation between the increased IL-6 level and the severity of viral infection. And
176 we will continue paying attention to this point in the future.

177 **Discussion**

178 This report, to our knowledge, is the first case series of patients with COVID-19 in
179 Anhui Province. As most patients remain hospitalized, we focus on the clinical and
180 laboratory profiles upon their admission. Epidemiological research shows that most
181 patients have been to Wuhan recently. Common symptoms were fever, cough, and
182 chest tightness. However, a significant proportion of patients presented with atypical
183 symptoms such as fatigue, muscle soreness and diarrhea. We also pay attention to
184 patients without fever in which cough may be the only or primary symptom.
185 Therefore, to avoid further transmission, screening and closely monitoring of each
186 suspect remain important. Further studies on the epidemiological characteristics of
187 these atypical cases are recommended.

188 The most common laboratory abnormalities observed in this study were decreased
189 total lymphocytes, prolonged APTT, elevated LDH, CRP and ESR. Similarities
190 abnormalities between COVID-19 and previously observed betacoronavirus,
191 MERS-CoV and SARS-CoV infection, have been noted [3, 6, 7]. These findings
192 suggest that COVID-19 can cause different degrees of hematological abnormalities
193 and damage of internal organs. The absolute value of lymphocytes was reduced in

194 more than 50% patients. The most significant was the decreased CD4⁺ T cell counts.
195 Previous studies of patients in Wuhan suggested virus invasion could induce a
196 cytokine storm syndrome (CRS) [5, 8]. Of the 14 patients with elevated IL-6, LYM%,
197 CD4⁺ and CD8⁺ T cell counts were significantly decreased and NEU%, CRP and
198 LDH levels increased significantly. Elevated IL-6 may be an important factor leading
199 to T lymphocytes damage and cellular immune deficiency. IL-6 could also be used as
200 an indicator to evaluate infection severity. Therefore, we conclude that IL-6 may be an
201 effective target for prevention or treatment of severe COVID-19 infection. Future
202 large-scale studies are needed to clarify the underlying mechanisms of disease
203 pathogenesis.

204 COVID-19 belongs to the betacoronavirus. As a single-stranded positive-sense
205 RNA virus, COVID-19 has 79.5% homology with SARS-CoV [9]. Similar to
206 SARS-CoV, angiotensin converting enzyme II (ACE2) is also the cellular entry
207 receptor of COVID-19 [9, 10]. ACE2 is highly expressed in human lung tissue,
208 gastrointestinal tract, vascular endothelial cells and arterial smooth muscle cells [11].
209 Therefore, all of the organs above may be targets for virus attack. ACE2 effectively
210 hydrolyzes the potent vasoconstrictor angiotensin II to angiotensin and is related to
211 hypertension, cardiac function and diabetes [12]. Liu et al. discovered that the
212 Angiotensin II level in the plasma samples increased markedly, suggesting that
213 COVID-19 could induce imbalanced renin-angiotensin system. Drugs of ACE
214 inhibitor (ACEI) and angiotensin receptor blocker (ARB) may be used as potential
215 treatment of COVID-19 infection [13]. As we can see, in patients with underlying
216 diseases, most of them have hypertension. However, no report has focused on the
217 correlation between antihypertensive agents with COVID-19 infection or disease
218 severity. Studies are necessary to evaluate the effectiveness of ACEI and ARB in the
219 future.

220 Currently, there is no specific therapy for patients with new coronavirus pneumonia.
221 The pathologic mechanisms of disease progression and exacerbation are also unclear.
222 How to relieve the clinical symptoms of critically ill patients, and reduce the severity

223 and mortality of patients still remains challenging. Considering the similarities
224 between SARS-CoV and COVID-19, some pre-clinical drugs against SARS-CoV
225 have been applied to COVID-19 patients. Remdesivir (RDV), a broad-spectrum
226 antiviral nucleotide analogue, is reported to treat MERS-CoV and SARS-CoV
227 infections effectively [14, 15]. A randomized controlled trial was initiated to
228 determine the safety and efficacy of RDV in patients with COVID-19 in Wuhan,
229 China recently. It is crucial to determine host tropism and transmission capacity in
230 terms of prevention of the virus infection [16]. Spike (S) protein mediates membrane
231 fusion through binding with ACE2. Monoclonal antibody against the S protein may
232 efficiently block the virus from entering the host. Convalescent plasma had also been
233 reported to be clinically useful to SARS and MERS patients [17, 18]. If available,
234 convalescent plasma should be used for critically ill patients with COVID-19.
235 However, the appearance of therapeutic plasma requires time and exists only in
236 recovered patients. In our opinion, comprehensive and supportive treatments are
237 essential in the early stage. Additionally, antiviral treatment in early stage and immune
238 activation blockers such as IL-6 blockers, IL-1 blockers in late stage could be tried to
239 control further disease progress leading to ARDS due to excessive immune activation.
240 Targeted treatment should depend on individual differences due to various disease
241 characteristics.

242 This study has several limitations. First, only 75 patients with confirmed
243 COVID-19 were included. It would be better to include as many patients as possible
244 to get a more comprehensive understanding of COVID-19. Second, more detailed
245 patient information, particularly treatment strategies and clinical outcomes, was
246 unavailable at the time of analysis. Regarding the inflammatory factors, we only
247 measured IL-6 level changes. Future studies should focus on changes of various
248 pro-inflammatory factors, ie IL-1, which may provide precise target treatment options
249 for different patients.

250 In conclusion, this study provides an early assessment of the clinical and laboratory
251 profiles of COVID-19 patients in Hefei, China. The clinical manifestation of

252 COVID-19 was nonspecific. Specific coronavirus antivirals show proven efficacies in
253 humans are unavailable to date. Antiviral therapy requires a comprehensive and
254 supportive treatment. Targeted therapy should also be determined based on individual
255 clinical manifestations and laboratory indicators.

256 **Funding**

257 This work is funded by the Key Research and Development Plan Project of Anhui
258 Science and Technology Department (YG, No. 201904b11020044).

259 **Contributors**

260 ZZ and MY collected the epidemiological and clinical data. JJX contributed to the
261 statistical analysis and drafted the manuscript. YY, TJ, HM, and AZ revised the final
262 manuscript. HH, WL, ZY, XZ, JX, CZ, LL, YL, CD and YQ contributed to clinical
263 and laboratory data acquisition. YG and XM had the idea for the study and take
264 responsibility for the integrity of the data and the accuracy of the data analysis.

265 **Acknowledgements**

266 We acknowledge all health-care workers involved in the diagnosis and treatment of
267 patients in Hefei. We thank the Chinese National Health Commission for coordinating
268 data collection for patients with COVID-19.

269 **Declaration of interests**

270 We declare no competing interests.

271 **References:**

272 1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus
273 in Wuhan, China. *Lancet* (London, England) **2020** 2020-01-01.

274 2. Hui DS, I Azhar E, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel
275 coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China. *INT J*
276 *INFECT DIS* **2020**;91:264-6.

- 277 3. Chan JF, Yuan S, Kok K, et al. A familial cluster of pneumonia associated with the 2019 novel
278 coronavirus indicating person-to-person transmission: a study of a family cluster. *The Lancet*
279 **2020**;395(10223):514-23.
- 280 4. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China,
281 2019. *N Engl J Med* **2020** 2020-01-24.
- 282 5. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019
283 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet* **2020**
284 2020-01-01;395(10223):507-13.
- 285 6. Ko JH, Park GE, Lee JY, et al. Predictive factors for pneumonia development and progression to
286 respiratory failure in MERS-CoV infected patients. *J Infect* **2016** 2016-11-01;73(5):468-75.
- 287 7. Liu CL, Lu YT, Peng MJ, et al. Clinical and laboratory features of severe acute respiratory
288 syndrome vis-a-vis onset of fever. *CHEST* **2004** 2004-08-01;126(2):509-17.
- 289 8. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel
290 Coronavirus – Infected Pneumonia in Wuhan, China. *JAMA* **2020** 2020-02-07.
- 291 9. Zhou P, Yang X, Wang X, et al. A pneumonia outbreak associated with a new coronavirus of
292 probable bat origin. *NATURE* **2020** 2020-02-03.
- 293 10. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from
294 Wuhan: An analysis based on decade-long structural studies of SARS. *J VIROL* **2020** 2020-01-29.
- 295 11. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2
296 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis.
297 *J PATHOL* **2004** 2004-06-01;203(2):631-7.
- 298 12. Warner FJ, Smith AI, Hooper NM, Turner AJ. Angiotensin-converting enzyme-2: a molecular and
299 cellular perspective. *CELL MOL LIFE SCI* **2004** 2004-11-01;61(21):2704-13.
- 300 13. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected
301 patients linked to viral loads and lung injury. *Science China Life Sciences* **2020** 2020-02-09.
- 302 14. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both

303 epidemic and zoonotic coronaviruses. *SCI TRANSL MED* **2017** 2017-06-28;9(396).

304 15. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and
305 combination lopinavir, ritonavir, and interferon beta against MERS-CoV. *NAT COMMUN* **2020**
306 2020-01-10;11(1):222.

307 16. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus:
308 implications for virus origins and receptor binding. *The Lancet* **2020**.

309 17. Marano G, Vaglio S, Pupella S, et al. Convalescent plasma: new evidence for an old therapeutic
310 tool? *Blood Transfus* **2016** 2016-03-01;14(2):152-7.

311 18. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong
312 Kong. *Eur J Clin Microbiol Infect Dis* **2005** 2005-01-01;24(1):44-6.

313

314

315

316

317

318

319

320

321

322

323

324 **Table 1. Demographics and baseline characteristics of 75 patients infected with**
325 **COVID-19**

Characteristics	No. (%)
Age, years, Median (IQR)	47 (34-55)
Range	16-91
<20	1 (1.33%)
20-39	25 (33.33%)
40-59	36 (48.00%)
60-79	11 (14.67%)
≥80	2 (2.67%)
Sex	
Female	33 (44%)
Male	42 (56%)
Exposure to Wuhan people	61 (81.33%)
Chronic medical illness	29 (38.67%)
Cardiovascular and cerebrovascular diseases	16 (21.33%)
Diabetes	6 (8.00%)
Chronic kidney disease	4 (5.33%)
Chronic liver disease	4 (5.33%)
Respiratory system disease	2 (2.67%)
Nervous system disease	1 (1.33%)
Malignant tumour	1 (1.33%)

326 Abbreviations: COVID-19, coronavirus disease 2019; IQR, interquartile range.

327 Data are presented as median (IQR) or n/N (%). N is the total number of patients with available

328 data.

329

330 **Table 2. Signs and symptoms of patients with COVID-19**

Signs and symptoms	No. (%)
Fever (°C)	
<37.3	9 (12.00%)
37.3-38.0	32 (42.67%)
38.1-39.0	32 (42.67%)
>39.0	2 (2.67%)
Dry cough	62 (82.67%)
Chest tightness	24 (32.00%)
Sputum production	22 (29.33%)
Fatigue	17 (22.67%)
Muscle soreness	9 (12.00%)
Poor appetite	9 (12.00%)
Diarrhea	7 (9.33%)
Sore throat	6 (8.00%)
Headache	5 (6.67%)
Shortness of breath	2 (2.67%)
Stomach ache	1 (1.33%)
Fever, cough and chest tightness	20 (26.67%)

Patients without fever (<37.3°C)	9
Dry cough	9 (100.0%)
Sputum production	2 (22.2%)
Fatigue	2 (22.2%)
Poor appetite	2 (22.2%)
Chest tightness	1 (11.1%)

331 Data are presented as n/N (%). N is the total number of patients with available data.

332

333 **Table 3. Laboratory results of patients infected with COVID-19 on admission to hospital**

Blood routine	Median (IQR)	Minimum	Maximum	Increased	Decreased
Leucocytes ($\times 10^9$ per L; normal range 3.5-9.5)	5.38(4.06-6.77)	2.01	16.53	4 (5.33%)	12 (16%)
Neutrophils ($\times 10^9$ per L; normal range 1.8-6.3)	3.54 (2.22-5.3)	1.09	14.43	9 (12%)	11 (14.67%)
Percentage of neutrophils (%; normal range 40-75)	69.70 (58.45-79.18)	29.38	91.61	29 (38.67%)	4 (5.33%)
Lymphocytes ($\times 10^9$ per L; normal range 1.1-3.2)	1.07 (0.68-1.53)	0.32	3.03	0 (0%)	40 (53.33%)
Percentage of Lymphocytes (%; normal range 20-50)	22.56 (12.50-32.59)	4.53	54.78	3 (4%)	32 (42.67%)
Platelets ($\times 10^9$ per L; normal range 125-350)	165 (132-216)	72	387	2 (2.67%)	14 (18.67%)
Haemoglobin (g/L; normal range 138(122-148.8)		78	162	18 (24%)	11 (14.67%)

115-150)

CD4 (cell/uL; normal range 410-1590)	451 (258-760)	79	2450	3 (4%)	31 (41.33%)
CD8 (cell/uL; normal range 238-1250)	305.6 (175.3-621.5)	77.49	1914	4 (5.33%)	28 (37.33%)
CD4/CD8 (normal range 0.9-3.6)	1.4 (1.21-1.78)	0.38	4.31	1 (1.33)	11 (14.67%)

Coagulation function

Activated partial thromboplastin time (s;

normal range 20-40) 38.7 (34.8-43.33) 24.4 52.3 30 (40%) 0

Prothrombin time (s; normal range

8.0-14.0) 14.5 (13.48-16.33) 10.7 19.9 44 (58.67%) 0

Blood biochemistry

Alanine aminotransferas (IU/L; normal

range 7-40) 23.00 (14-43) 8 171 15 (20%) 0

Aspartate aminotransferase (IU/L; normal

range 13-40) 27.00 (21-37) 14 89 14 (18.67%) 0

Total bilirubin ($\mu\text{mol/L}$; normal range

3.4-21.0) 14.50 (11.1-18.2) 3.7 55.9 12 (16%) 0

Blood urea nitrogen (mmol/L; normal

range 2.6-7.5) 4.02 (3.03-5.41) 1.5 24.34 3 (4%) 9 (12%)

Serum creatinine ($\mu\text{mol/L}$; normal range

41-81) 68 (58-77) 31 1561 15 (20%) 3 (4%)

Creatine kinase (IU/L; normal range

22.0–269.0) 89.05 (54.95-150.8) 23 1063 8 (10.67%) 0

Lactate dehydrogenase (U/L; normal

range 120-250) 233 (176.5-313) 12.5 936.0 33 (44%) 1 (1%)

Troponin I (ug/L; normal range 0-0.3)	0.09 (0.07-0.27)	0.03	27	13 (17.33%)	0
---------------------------------------	------------------	------	----	-------------	---

Infection-related biomarkers

C-reactive protein (mg/L; normal range 0-8.0)	13.6 (3.8-48.2)	0.5	150	46 (61.33%)	/
---	-----------------	-----	-----	-------------	---

Erythrocyte sedimentation rate (mm/h; normal range 0-15) (n=45)	30.10 (11.5-69)	0.17	145	30 (66.67%)	/
---	-----------------	------	-----	-------------	---

Procalcitonin (ng/mL; normal range 0-0.5) (n=59)	0.16 (0.12-0.21)	0.1	1.87	2 (3.39%)	/
--	------------------	-----	------	-----------	---

Interleukin-6 (pg/mL; normal range 0-7.0) (n=49)	6.21(5.33-7.18)	4.25	28.56	14 (28.57%)	/
--	-----------------	------	-------	-------------	---

Co-infection

Adenovirus	1				
------------	---	--	--	--	--

334 Data are median (IQR) or n/N (%). The maximum and minimum values have been presented.

335 Increased means over the upper limit of the normal range and decreased means below the lower
336 limit of the normal range.

337

338 **Table 4. Laboratory findings of patients with elevated and normal IL-6 level**

	Median (IQR)		P value
	Elevated IL-6 (n=14)	Normal IL-6 (n=35)	
Blood routine			
Leucocytes ($\times 10^9$ per L; normal range 3.5-9.5)	6.23 (4.13-6.86)	5.44 (3.9-6.63)	0.45
Neutrophils ($\times 10^9$ per L; normal range 1.8-6.3)	5.09 (3.36-5.66)	3.43 (1.81-4.75)	0.1055
Percentage of neutrophils (%; normal range	78.02 (66.88-85.81)	70.54 (58.45-78.32)	0.0443*

40-75)			
Lymphocytes ($\times 10^9$ per L; normal range 1.1-3.2)	0.79 (0.53-1.11)	1.05 (0.67-1.79)	0.1055
Percentage of Lymphocytes (%; normal range			
20-50)	14.61 (8.52-24.03)	21.58 (14.15-32.59)	0.0264*
CD4 (cell/uL; normal range 410-1590)	322 (138.5-420.5)	511.6 (242.8-816.5)	0.0367*
CD8 (cell/uL; normal range 238-1250)	153.4 (119.2-228.4)	305.4 (179.6-651.8)	0.0021*
CD4/CD8 (normal range 0.9-3.6)	1.57 (0.930-2.46)	1.41 (0.53-1.78)	0.2081
Blood biochemistry			
Alanine aminotransferas (IU/L; normal range			
7-40)	27.5 (13.5-43.75)	23 (16.00-47)	0.9782
Aspartate aminotransferase (IU/L; normal range			
13-40)	27 (21.75-39.50)	28 (20-38)	0.6028
Total bilirubin ($\mu\text{mol/L}$; normal range 3.4-21.0)	13.45 (9.38-16.45)	14.3 (10.7-18.3)	0.5217
Serum creatinine ($\mu\text{mol/L}$; normal range 41-81)	72.5 (59.75-81.75)	67 (60-79)	0.5727
Creatine kinase (IU/L; normal range 22.0–269.0)	86.2 (66.95-240.3)	92.85 (56.45-144.3)	0.6619
Lactate dehydrogenase (U/L; normal range			
120-250)	318 (252.5-408.8)	230 (177.8-319.3)	0.027*
Ttroponin I ($\mu\text{g/L}$; normal range 0-0.3)	0.26(0.09-0.77)	0.08 (0.07-0.29)	0.0955
Infection-related biomarkers			
C-reactive protein (mg/L; normal range 0-8.0)	76.45 (21.53-110.5)	9.0 (3.26-23.10)	0.0003*
Erythrocyte sedimentation rate (mm/h; normal			
range 0-15)	69 (19.50-115.4)	29.10 (13.40-62.25)	0.127
Procalcitonin (ng/mL; normal range 0-0.5)	0.23 (0.17-0.29)	0.15 (0.11-0.18)	0.0017*

339 Abbreviation: IL-6, Interleukin-6.

340 Data are presented as median (IQR) or n/N (%). Statistical analysis, Mann-Whitney test. P values
341 indicate differences between patients with elevated and normal IL-6 level. * P < .05 was
342 considered statistically significant.

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360




361

362 **Figure legend**

363 Figure 1. Differences of laboratory findings between patients with elevated and normal IL-6 level.

364 (a) Percentage of NEU and LYM, (b) CD4⁺ and CD8⁺ T cell counts, (c) Detection of LDH levels,
365 and (d) Changes of the infection indicator, CRP in two groups. Data are presented as median
366 (interquartile range, IQR) and analyzed by Mann-Whitney test. All statistical analyses were
367 performed using GraphPad Prism 8.3. P values indicate differences between patients with elevated
368 and normal IL-6 level (* p<.05, ** p<.005, *** p<.001). P <.05 was considered statistically
369 significant.

370 Abbreviations: IL-6, Interleukin-6; lymphocytes percentage, LYM%; neutrophil percentage,
371 NEU%; lactate dehydrogenase, LDH; C-reactive protein, CRP.

a**b****c****d**